The lack of efficient therapeutic options for many severe disorders including cancer spurs demand for improved drug delivery technologies. Nanoscale drug delivery systems based on poly(ethylene glycol)-poly(ε-caprolactone) copolymers (PEG-PCL) represent a strategy to implement therapies with enhanced drug accumulation at the site of action and decreased off-target effects. In this review, we discuss state-of-the-art nanomedicines based on PEG-PCL that have been investigated in a preclinical setting. We summarize the various synthesis routes and different preparation methods used for the production of PEG-PCL nanoparticles. Additionally, we review physico-chemical properties including biodegradability, biocompatibility, and drug loading. Finally, we highlight recent therapeutic applications investigated in vitro and in vivo using advanced systems such as triggered release, multi-component therapies, theranostics, or gene delivery systems.
Introduction
Nanomedicine is an emerging discipline in pharmaceutical science. Engineered nanomaterials (ENM), defined by one or more external dimension in the size range of 1 nm to 100 nm, are used to implement various drug delivery platforms [1, 2] . Many promising candidates are in clinical and preclinical research and some nanoparticle (NP) formulations, e.g. Genexol-PM™, recently gained market approval by health care authorities such as the FDA [3] [4] [5] . Different materials are used for the production of such nanoparticulate drug delivery systems (nanoDDS) including inorganic NPs, viral NPs, lipid based NPs, and polymer based NPs [3] . Among these, synthetic copolymers gained much attention due to their versatile and tunable chemistry. Synthetic copolymers can be used to produce solid sphere nanoparticles, micelles, vesicular polymersomes, polyplexes, polymer-drug conjugates, and dendrimers [6] . A schematic overview about polymer-based nanostructures is given in Fig. 1A . Notably, copolymers of the hydrophilic PEG and hydrophobic PCL are characterized by a high biocompatibility and biodegradability (Fig. 1B) . PEG has a long history of use in therapeutic strategies. PEGylation of therapeutic proteins or liposomes is used to reduce immunogenicity and toxicity, prolong blood circulation time, change biodistribution, and optimize protein activities [4, [7] [8] [9] [10] [11] [12] . PCL, a semi-crystalline and biodegradable polymer, was successfully used in medical devices and tissue engineering [13] [14] [15] [16] . In this review, we will focus on the synthesis, production, characterization, and application of PEG-PCL-based nanomedicines. Therapeutic effects induced in vivo via targeted and non-targeted drug delivery, application routes, triggered drug release, theranostic NPs, and progress in PEG-PCL-based gene delivery strategies will be discussed. For the sake of simplicity, PEG-b-PCL will be used for di-block copolymers of PEG and PCL, whereas PEG-PCL will be used for copolymers of PEG and PCL (and others) with various architectures.
Synthesis
During the last decades a vast number of different PEG-PCL-based copolymers have been developed and various synthetic routes have been investigated. The most established method to synthesize PEG-b-PCL di-block copolymers is the ring-opening polymerization of ε-caprolactone (CL) with methoxy poly(ethylene glycol) (mPEG) as an initiator using catalysts such as stannous octate (Sn(Oct) 2 ), calcium, or aluminum complexes [17] [18] [19] [20] [21] [22] [23] . Alternative synthesis routes using biocatalysts (e.g. enzymes) or using "click" chemistry were described [24, 25] . For the synthesis of PEG-b-PCL di-block copolymers, various block lengths of PEG and PCL were combined. The molecular weight of the PCL block is mainly controlled by the molar ratio of CL to the initiator mPEG [26] . The mass or volume fraction (f) of each block and the molecular weight of the copolymer mainly dictate the resulting structure of the NP [27] [28] [29] [30] [31] . Amphiphilic block copolymers with a hydrophilic weight fraction similar to phospholipids (f ≈ 25-45%) tend to form vesicular structures, a hydrophilic weight fraction of f > 50% usually results in micellar structures [27, 30, 32] . The composition of the block copolymers can be optimized using methods such as full factorial design [33] . In addition to di-block copolymers, tri-block copolymers, i.e. PCL-b-PEG-b-PCL (PCEC) and PEG-b-PCL-b-PEG (PECE), as well as branched, brushed, and star-shaped PEG-PCL copolymers were generated. Synthesis strategies using different PEG variants as initiator, "click" chemistry, or coupling reagents such as hexamethylendiisocyanate (HMDI) or N-hydroxysuccinimide (NHS) and N,N′-dicyclohexylcarbodiimide (DCC) resulted in a big arsenal of PEG-PCL copolymers for the potential use in drug delivery [23, [34] [35] [36] [37] [38] [39] [40] [41] . These polymers show different assembly behavior, drug loading properties, and cellular uptake behavior and can thus be chosen according to the therapeutic strategy [40, 42] . PEG-PCL graft copolymers (PEG-g-PCL) were synthesized via a thiol-yne approach [43] . Polymer amphilicity was highly tunable and easy to control. Thus, PEG-PCL copolymers with a broad range of molecular weights, various architectures, and tunable amphiphilicity can be synthesized. Using systematic approaches such as design of experiments (DoE), tailor-made polymers for specific drugs can be produced and NPs with a homogeneous size distribution can be prepared.
Nanoparticle preparation methods
PEG-PCL NPs for biomedical applications can be produced using various types of methods. Mostly, these are based either on spontaneous self-assembly or emulsification. A suitable protocol depending e.g. on stability of the drug or the targeting ligand in organic solvents or at high temperatures can be chosen.
In solvent-displacement, also called nanoprecipitation, the polymer is dissolved in a water-miscible organic solvent and subsequently, an aqueous phase (i.e. non-solvent) is added dropwise. Due to reduced polymer solubility and interfacial hydrodynamic phenomena (i.e. Marangoni effect), spontaneous NP formation is induced. The organic solvent is subsequently removed by evaporation [44, 45] . Various organic solvents such as acetone, dimethylformamide (DMF), or tetrahydrofuran (THF) were used in the production of PEG-PCL NPs [17, 18, 42, [46] [47] [48] [49] [50] . The type of organic solvent, the ratio of organic to aqueous phase, and the order of phase addition can be changed to control NP size, morphology, and to optimize drug loading [51] . Recently, PEG-b-PCL micelles with mean diameters of 82.9 nm, 87.8 nm, and 109.0 nm were prepared by using either acetonitrile, acetone, or THF as organic phase [51] . A modification of the solventdisplacement method is the so-called dialysis method. In this method, the polymer is dissolved in a water-miscible organic solvent, mixed with an aqueous phase, and then dialyzed against aqueous media [22, 52, 53] . Film rehydration is widely used in the production of liposomes and was also used for the production of polymer NPs [54] [55] [56] [57] . In film rehydration, the polymer is dissolved in an organic solvent (e.g. chloroform, methanol, or acetone) that is subsequently removed by evaporation to obtain a thin polymer film. After rehydration of the polymer film, small micelles are formed that can further rearrange to form spherical micelle-like NPs or vesicles (i.e. polymersomes) [58] . An adaptation of film rehydration, melting/sonication, was developed [59] . Heating of the sample above the polymer melting temperature (T m ) and subsequent sonication after rehydration of the polymer thin film led to the formation of mono-disperse PEG-b-PCL micelles [59] [60] [61] [62] . Several approaches for the preparation of NPs using emulsification or double emulsification for the encapsulation of hydrophilic drugs were described. In the so-called emulsion solvent evaporation technique, the polymer is dissolved in a volatile and waterimmiscible organic solvent such as dichloromethane (DCM) or chloroform. This solution is emulsified in an aqueous phase containing stabilizers (e.g. polyvinyl alcohol (PVA), trehalose, or sodium cholate) in combination with ultrasonication or other methods. The organic solvent is then removed by heat and NP formation is induced [44, 45, [63] [64] [65] [66] [67] . Especially, novel methods such as microfluidics have gained much attention for the preparation of PEG-PCL NPs. Microfluidic mixing of PEG-b-PCL-b-poly(ethylene imine) (PEI) for siRNA complexation resulted in smaller and more homogeneous micelles, enhanced siRNA stability, and higher transfection efficiency as compared to micelles produced by bulk mixing (i.e. solvent-displacement) [68] . Interestingly, this technique can be used for scale-up production as well as in process-sterilization of NPs which is a prerequisite for the preparation of clinical trial samples [69] [70] [71] . Importantly, the great variety of preparation methods for the production of PEG-PCL NPs offers the possibility to choose the ideal strategy, e.g. depending on the drug stability in organic solvents or at different temperatures. Recently developed preparation methods for different drugs and PEG-PCL copolymers are summarized in Table 1 .
Degradation and colloidal stability

Stability and degradation
In order to improve the therapeutic value (i.e., biocompatibility and excretion of nanoparticles), the degradability of polymer nanoparticles is a major issue. During the last years, the biodegradation of PCL and PEG-PCL-based medical devices was studied extensively [16, [72] [73] [74] [75] . It has been shown that controllable factors such as polymer composition and molecular weight as well as other factors like temperature and pH strongly influence the degradation rate, reflected by a decreasing molecular weight of the polymer [76] [77] [78] [79] . Mainly, polymers can degrade and erode via surface or bulk process [80, 81] . The latter is defined by polymer loss from the entire volume and seems to be the mechanism highly contributing to the degradation of PCL-based films and medical devices [82] . In an initial phase, a random hydrolytic chain scission can be observed followed by polymer weight loss and diffusion 
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Journal of Controlled Release 260 (2017) [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] of small CL oligomers out of the polymer bulk. This process is autocatalytic, i.e. free carboxylic groups catalyze the cleavage of remaining ester groups [82] . Consequently, water-soluble and insoluble CL oligomers as well as PEG segments were identified as first degradation products of PEG-PCL [83] . Additionally, enzymes such as lipases increase PEG-PCL degradation in vitro. These enzymes are present intra-and extracellularly and catalyze the hydrolysis of triglycerids. However, their contribution for the in vivo degradation is still unclear [80, 82, 84] . Regarding PEG-PCL NPs, several other factors such as route of administration and NP characteristics (e.g. size, shape, and zeta potential) strongly influence the degradation and elimination from the body. A study on the in vivo degradation of di-block copolymer micelles showed, that in vitro degradation kinetics should be used with precaution to predict the in vivo situation. The in vivo degradation was much faster than the weight decrease measured in vitro [84, 85] . Polymer bioresorption, degradation, and subsequent elimination or metabolism of the degradation products will determine the residual time in the body after administration [73] . Colloidal stability and biodistribution of the NP will therefore dramatically influence the mean residual time (MRT) of the polymer [85, 86] . PEG-PCL micelles are stable in phosphate buffered saline (PBS) for months [67] . However, in biological media such as cell culture medium or blood, protein opsonization can affect the micelle stability [87] [88] [89] . It is thus recommended, that the colloidal stability should be tested in an environment similar to in vivo conditions [89, 90] . For example, stability of PEG-PCL micelles was tested in serum containing medium. In contrast to the high stability in PBS, micelles showed changes in size and size distribution in a time and serum-concentration dependent manner [91] [92] [93] . Large NP aggregates can be taken up by the mononuclear phagocyte system (MPS) [94, 95] . In contrast, individual PEG-PCL block copolymers (unimers) that may occur after NP disassembly can be cleared via different mechanisms. When PEG-b-PCL was injected into experimental animals as unimers (i.e. below the critical aggregation concentration; CAC), a high uptake by liver, spleen, and kidney already after one hour of injection was observed as indicated by high tissue to plasma concentration ratios of 1.90, 1.30, and 1.70, respectively [96] . As a consequence, PEG-b-PCL unimers were rapidly removed from the plasma compartment (half-life: 10.2 h), whereas PEG-b-PCL micelles remained three times longer in the blood circulation [96] . Importantly, resulting metabolites did not accumulate and were cleared from the body via feces and urine efficiently [97] . A schematic overview about PEG-PCL NP behavior after injection is given in Fig. 2 .
Shelf half-life
To prolong the shelf half-life of PEG-PCL-based formulations and to prevent premature nanoparticle degradation, NPs can be freeze-dried. This technique is widely used in pharmaceutical industry to increase storage stability of drugs, especially biologics. In order to preserve the physico-chemical characteristics of the NP formulation after reconstitution, cryoprotectants and stabilizers can be added to the formulation to optimize freeze drying [98] . Layre and colleagues analyzed the effect of different additives on the lyophilization of PEG-b-PCL micelles. Best results with only little aggregation of micelles after reconstitution were obtained by adding the surfactant Poloxamer 188 and trehalose to the micelle formulation before freeze-drying [99] . Importantly, reconstituted samples were still able to exert their biologic activities [100] .
Biocompatibility and safety
The repeated use of nanomedicine products bears the risk of unwanted side-effects. Thus, an important step in the development of a nanomedicine product is the assessment of any safety risk. Especially, the biocompatibility and cytotoxicity of the nanocarrier on an acute and chronic level (i.e. short and long-term effects) have to be evaluated. PEG, PCL, and PEG-PCL products were approved by health care authorities such as the FDA [97, 101, 102] . Long-term experience with medical products consisting of these materials revealed a high biocompatibility and no concerns about toxic side effects [15, 16, 72] . In nanotoxicology, however, additional factors such as particle size, geometry and morphology, surface-to-volume ratio, and protein adsorption capacity of NPs have to be considered. Thus, each new NP formulation should be tested individually for toxic effects [103] . A precise physico-chemical characterization of NP properties is a prerequisite for any nanotoxicity profiling. Many PEG-PCL NPs in vitro toxicity studies (i.e. MTT cell viability assays or cell growth assays) using various established cell lines were performed. PEG-PCL-based NPs within a size range of around 20 nm to 200 nm and slightly negative zeta potentials were tested. No or only minor toxic effects on cell viability were detected up to concentrations of 1.5 mg/mL [22, 42, 49, 61, [104] [105] [106] [107] [108] [109] [110] [111] . Shi and coworkers incubated human umbilical vein endothelial cells (HUVEC) with 0.2 mg/mL up to 1.2 mg/mL of PEG-b-PCL micelles for 48 h and observed no decrease in cell viability when analyzed using the MTT assay [105] . A slight elevation of reactive oxygen species (ROS) levels in macrophages was observed in vitro, whereas no induction of nitric oxide (NO) was detected [112, 113] . In addition, PEG-PCL micelles did not induced hemolysis when incubated with freshly isolated human blood or rabbit erythrocytes [61, 106, 113] . Although in vitro studies revealed no cytotoxic effects of PEG-PCL NPs, data from experimental animals are needed to confirm such findings [114] . Several studies on the in vivo toxicity of PEG-PCL micelles were conducted in mice and rats. In vivo studies using high single doses of PEG-PCL micelles up to 2.4 g/kg injected i.v. did not reveal any signs of acute toxicity. No histological changes in heart, liver, spleen, lung, and kidney were observed. Behavior and food consumption of the animals were comparable to untreated animals [21, 113] . PCEC was injected s.c. at a dose of 5 g/kg. Again, no toxic effects or behavioral changes were observed in BALB/c mice [115] . It should be noted that BALB/c mice are frequently used for immunological studies due to their potential to develop (Th2-biased) immune responses. No changes in plasma levels of serum aspartate transaminase (AST) and alanine transaminase (ALT) were measured in animals treated i.v. with a single dose of 36 mg/kg dexamethasone-loaded PEG-b-PCL micelles (the used concentration of the model compound dexamethasone was 0.8 mg/kg). A slight activation of the complement system was observed as measured by elevated C3a levels in treated rats [116] . PEG-b-PCL micelles induced no changes in levels of inflammatory factors in mice plasma when injected i.v. at a dose of 8 mg/kg. IL-6, IL-10, IL-12p70, IFN-γ, TNF, and MCP-1 levels were comparable to control animals treated with saline [112] . PCEC micelles did not induce any mutagenic effects in vitro and in vivo [117] . PEG-b-PCL micelles were also tested for sub-chronic toxicity in vivo. Daily i.v. administration of 100 mg/kg for one week in rats and mice did not induce any changes in weight gain. No acute inflammation or toxic effects on liver, kidney, or the brain parenchyma were observed [117, 118] . AST, ALT, total bilirubin, ureanitrogen (BUN), and creatinin levels were comparable to those of control animals treated with saline [118] . PEG-PCL NPs are well tolerated and have not induced any acute toxicity in experimental animals in vivo after single or multiple dosing. No changes in histology or markers of inflammation were detected. Thus, it is expected that PEG-PCL based nanomedicines should be safe and well tolerated in human. As of today, long-term toxicity studies were performed in experimental animals only.
Drug loading and release
General principles
In order to induce a desired pharmacological effect, drugs of interest can be combined with PEG-PCL-based formulations. Therefore, noncovalent drug encapsulation (based on hydrogen bonding, hydrophobic interactions, or ionic interactions) or covalent drug conjugation can be used [119] . Several factors such as the solubility of the drug, the affinity of the drug to the polymer, the NP core volume, and the ability of the drug to self-aggregate can influence the drug loading content (DLC), i.e. the mass ratio of drug to polymer [120] . Paclitaxel loading content in PEG-b-PCL micelles for example increased with increasing length of the hydrophobic PCL block [121] . In contrast, no significant increase was observed when a similar experiment was performed with the less hydrophobic compound doxorubicin [17] . Besides experimental approaches, physico-chemical models were used to predict drug loading and stability based on polymer-drug compatibility parameters [122] . The Flory-Huggins interaction parameter (Χ FH ), for example, was successfully used to characterize drug polymer compatibilities [123] [124] [125] . Methods to calculate interaction parameters of PEG-PCL copolymers and various drugs based on molecular dynamics were developed [126, 127] . A rational coarse grain model for the partitioning of paclitaxel in PEG-b-PCL micelles and worm-like nanocarriers was generated. The authors showed that not only the composition of the polymer, but also the NP shape heavily influences drug loading [32] . Worm-like structures are characterized by increased polymer packaging constraints: PEG moieties show a higher packaging density on surfaces with a reduced curvature. Under this condition, PEG chains extend resulting in an increased thickness of the outer PEG layer [32] . Consequently, worm-like structures showed a two fold increase in drug loading as compared to spherical NPs [32] . Such methods can facilitate formulation screening and can be used for the rational design of novel drug-specific polymers and nanocarriers [122, [128] [129] [130] [131] . It should be noted that combination of a given drug with a nanocarriers can strongly influence the PK profile of the drug and its pharmacological effect [132] . Encapsulated drugs can be released from NPs via diffusion through the polymer matrix or water filled pores or after erosion of the polymer micelle [133] . In addition to passive release, triggered release of drugs may be favorable as discussed in Section 8.3 of this review. For the analysis of drug release from PEG-PCL-based nanomedicines in vitro, different methods can be applied: The gold standard is dialysis against an appropriate recipient medium. Alternative methods make use of continuous flow systems or microdialysis [134, 135] . Due to missing sink conditions, extrapolation of these in vitro results to the in vivo situation is difficult. Other approaches, such as determination of the unbound fraction (fu) of the drug when drug loaded PEG-PCL micelles are incubated with red blood cells are therefore good alternatives to simulate in vivo stability and release behavior [136] . Methods to measure the intracellular drug release after NP uptake [137] can additionally be of particular interest when "smart" drug formulations with triggered release kinetics upon intracellular stimuli exposure (e.g. pH) are designed. Scarpa and colleagues established a method to quantify the real-time intracellular release of a fluorescent dye from PEG-b-PCL NPs after in vitro cell uptake [138] .
Examples
PEG-PCL block copolymers and their derivatives offer a large variety of physico-chemical features including variable hydrophilic and lipophilic properties and self-assembly into nano-sized structures. A vast number of active compounds can be encapsulated into PEG-PCLbased nanoDDS. Drugs with molecular weights ranging from 177 g/mol up to 1269 g/mol and a wide range of XLogP3 [139] values (− 9.9 to 7.5) were successfully incorporated into PEG-PCL NPs. XLogP3 is a method for LogP computation (i.e. prediction of octanol-water partition coefficients) and can thus be used to characterize the lipophilicity of compounds [139] . A detailed overview about drug-loaded PEG-PCLbased nanoDDS is given in Table 1 . The following section highlights some examples from the preclinical setting.
Sulforaphane, a potent natural compound against various cancers lacks of chemical stability (i.e. sensitivity to heat and oxygen) and suffers from poor water solubility. Sulphoraphane was encapsulated in PEG-b-PCL micelles with a homogeneous size distribution around 120 nm and a high encapsulation efficiency (EE) [111] . This formulation showed therapeutic activity in MCF-7 breast cancer cells in vitro. Paclitaxel, an inhibitor of the microtubule rearrangement, is widely used in cancer therapy. Due to its low water solubility, the excipient Cremophor EL is used in the approved formulation (Taxol™). However, this excipient has certain limitations and is characterized by severe toxic side effects [140, 141] . To overcome this issue, PEG-b-PCL micelles were successfully used in various experimental settings for the encapsulation of paclitaxel [63, 64, 66, 118, 142, 143] . Xin and coworkers produced PEG-b-PCL NPs with a high EE of > 90% and a DLC of 8.2% that were tested in vitro and in vivo in experimental animals and showed promising results [66, 118, 142] . Another PEG-b-PCL-based formulation of paclitaxel showed a remarkable stability with < 50% of the initial drug content released within 24 h [64] .
Co-encapsulation strategies, chemical optimization of the drug, and active drug loading strategies were successfully used to improve EE and DLC of PEG-PCL NPs. Rapamycin, used for immunosuppression and cancer treatment, was encapsulated in PEG-b-PCL micelles. Interestingly, optimization of the encapsulation protocol by co-incorporation of the excipient α-tocopherol increased the EE and the release half-life of rapamycin [144] . A high EE of 11% and a slow drug release (50% released after 31 h) were achieved. The authors speculated that similar chemical motifs in α-tocopherol and rapamycin as well as their high lipophilicity were major reasons for this phenomenon. In another study, a PEG-b-PCL micelle formulation of TGX-221, a PI3K inhibitor, was developed. A fast release half-life of < 1 h was observed. In sharp contrast, synthesis of a TGX-221 prodrug, i.e. BL05-HA, resulted in significantly improved micelle stability and an increase of the release half-life to 6.5 days. Still, the micelle formulation showed selective inhibition of prostate cancer cells in vitro [145] . Active drug loading strategies using e.g. transmembrane pH gradients were developed for liposomal formulations [146] [147] [148] and adopted to PEG-PCL NPs. For example, active loading of doxorubicin into PEG-b-PCL polymersomes was performed using proton gradients. Despite the high membrane thickness of 16 nm, a high EE of 96% was achieved [149] . It can be concluded that various parameters can influence loading efficiency into PEG-PCL NPs and drug release. Optimized PEG-PCL copolymers can be designed and preparation protocols adapted to improve encapsulation of specific drugs. Application of PEG-PCL-based nanoDDS inducing therapeutic effects in both in vitro and in vivo settings will be highlighted in the following sections.
Pharmacokinetics and biodistribution
A prerequisite for successful active or passive drug targeting is a long plasma half-life. To obtain long circulating formulations, several factors such as size, shape, and surface characteristics need to be considered in the design of NPs [150, 151] . NPs with a size below 5-6 nm can be excreted by renal filtration, while NPs with > 500 nm in diameter or with a positive surface charge are recognized and removed from the blood circulation by the reticulo-endothelial system (i.e. MPS) [152] [153] [154] [155] [156] . Especially, protein opsonization plays a critical role in cellular uptake of NPs [157] . PEGylation of NPs was shown to influence the total amount and composition of adsorbed proteins on the NP surface; thus, changing NP-cell interactions as well as NP PK properties [8, 11, [158] [159] [160] . Most PEG-PCL NPs used in in vitro or in vivo studies showed a size between 20 and 200 nm and a slightly negative zeta potential, both indicators for long circulating nanocarriers [161, 162] . Several in vivo PK and biodistribution studies in experimental animals (i.e. rats and mice) were performed [20, 50, 64, 96, 106, 136, 142, [163] [164] [165] . Different strategies for the labeling and detection of PEG-PCL NPs were applied, i.e. tracking the drug or the nanocarrier in vivo. In most experimental settings, drug loaded PEG-PCL NPs were produced. Drug concentrations were analyzed by high performance liquid chromatography (HPLC), mass spectrometry (LC-MS/MS), or liquid scintillation counting (LSC) and used to determine the PK parameters of the drug carrier [20, 50, 64, 107, 136, 165] .
As noted above, morphology and polymer characteristics of PEG-PCL NPs can vary considerably. Consequently, a certain variability of PK parameters can be observed as summarized below. PEG-b-PCL micelles with an average hydrodynamic diameter of 89.3 ± 15.3 nm loaded with cyclosporine A were injected i.v. into male Sprague-Dawley rats at a dose of 5 mg/kg. A low volume of distribution (V D ) of 0.167 L/ kg, a slow clearance (CL) of 0.0223 L/kg/h, and a high mean residual time (MRT) of 11.1 h were measured [163] . Similar results were observed for paclitaxel-loaded PEG-b-PCL micelles with a size of ≈ 100 nm [20] . PCEC NPs loaded with curcumin and a size of 38.9 nm were administered in Wistar rats at a dose of 15 mg/kg via single tail vein injection. The PK parameters of curcumin were dramatically changed. A V D of 0.216 L/kg, a CL of 0.005 L/kg/h, and a long MRT of 30.07 h were observed [166] . Capsaicin-loaded PEG-b-PCL micelles were administered orally to Sprague-Dawley rats. Capsaicin is characterized by a high hepatic first pass metabolism and a short plasma half-life. Encapsulation in PEG-b-PCL micelles with an average diameter of 82.5 ± 0.5 nm resulted in a 6-fold increase in AUC and prolonged the MRT by a factor of 3 [67] . Whereas these studies aimed to detect changes in PK parameters of the encapsulated drug, covalent labeling of PEG-PCL by tritium or gamma emitters such as 99 mTC was used to analyze polymer concentration by scintillation counting [96, 164] . Tritium labeled PEG-b-PCL micelles with a size of 56 ± 6 nm were injected i.v. into female BALB/c mice at a dose of 250 mg/kg. Comparable to the results obtained in rats (see above), a low V D of 1.75 mL (corresponding to 0.6 L/kg), a low CL, and a high MRT of 43.3 h were observed [96] . Up to 12 h after i.v. injection, only small fractions of PEG-PCL micelles were detected in liver, spleen, and kidney [96, 163, 164] . Near-infrared (NIR) imaging is a promising noninvasive imaging technique to study NP distribution in vivo using NIR dyes such as DiR. NIR imaging was used to further analyze accumulation of NPs in various tissues and tumors [64, 116, [167] [168] [169] [170] [171] [172] . Moreover, NIR dye loaded PEG-b-PCL NPs were proposed as tools to guide surgical resection in cancer patients suffering from tumors with pronounced EPR effects [169] . Due to their favorable pharmacokinetic profile, i.e. long-circulating properties, PEG-PCL NPs offer a promising option for nano-based drug formulations. In addition, this characteristic is an important prerequisite for further implementation of drug targeting strategies. Notably, a big toolbox of labeling and detection strategies of PEG-PCL NPs was developed that is applicable for various PEG-PCL constructs. Nevertheless, comparison of PEG-PCL NPs to the gold standard long-circulating drug delivery system, i.e. PEGylated liposomes, should be performed in the same experimental settings.
Applications in the preclinical setting
In order to improve the therapeutic index of a drug, different approaches in combination with PEG-PCL copolymers were developed. The following section will focus on non-targeted (i.e. passive) and targeted (i.e. active) delivery systems. In addition, advanced technologies such as stimuli-responsive systems, theranostics, and gene therapeutics will be highlighted. In each section, examples will be given with increasing complexity from small molecules to macromolecules or from single drug applications to drug combinations. Fig. 3 summarizes various applications of PEG-PCL-based NPs.
Non-targeted drug delivery
In contrast to some organs (e.g. the brain) that are highly protected by tightly sealed endothelial cell layers, other tissues are characterized by fenestrated (i.e. permeable) blood vessels (e.g. the liver). Interestingly, diseases such as cancer and inflammatory states are also linked with leaky vasculature [173, 174] . In cancer for example, rapid cell proliferation increases the local demand for oxygen and nutrients that requires the generation of new blood supply. These fast growing blood vessels are often irregular and can have fenestrations of 100 nm up to 2 μm, depending on the localization and type of tumor [175] [176] [177] . As a consequence, macromolecules or long-circulating NPs can extravasate and can therefore passively accumulate in the tumor. Additionally, many solid tumors lack in sufficient lymphatic drainage and thus clearance of nanoparticles from the interstitial space is reduced [178] . This phenomenon is called enhanced permeability and retention (EPR) effect [179] . The efficiency of passive tumor targeting strongly depends on tumor biology (e.g. the type and location of the tumor, the extracellular matrix, and the presence of necrotic domains) and the physico-chemical properties of the NP such as size, shape, and zeta potential [175, 180, 181] . Because of significant inter-and intra-individual differences in tumor biology, screening of patients that could potentially benefit from long-circulating NPs using diagnostic tools needs to be considered [182, 183] . Furthermore, detailed characterization of NPs is required, since even small differences in e.g. the particle diameter can dramatically influence the potential tumor accumulation [167] . A non-targeted micellar PEG-b-PCL formulation of paclitaxel was injected i.v. in mice carrying MDA-MB-468 breast cancer cells in their mammary fat pad and compared to the approved formulation Taxol™. Mice were treated twice per week at a dose of 15 mg/kg via i.v. injection and the tumor volume was measured. Whereas a relapse in tumor growth was observed in animals treated with Taxol™, a constant reduction of the tumor volume was achieved in animals treated with paclitaxel PEG-b-PCL micelles [143] . PEG-b-PCL micelles loaded with doxorubicin and a size around 100 nm preferentially accumulated in tumor tissue when administered i.v. in Ehrlich-ascites tumor (EAT)-bearing mice. Animals treated with the micelle formulation showed a reduced tumor size as compared to animals treated with free doxorubicin [164] . Doxorubicin-loaded PCEC with a size of 130.8 nm showed a 2.38-fold higher accumulation after 24 h in tumor tissue as compared to free doxorubicin after single i.v. injection in EMT-6 breast cancerbearing mice [62] . Chemotin, a hydrophobic anti-cancer compound, was encapsulated in PECE micelles. PECE NPs were injected in transgenic zebrafish, xenograft-bearing zebrafish, and mice. Chemotin showed increased intratumoral accumulation when injected as micelle formulation and inhibited angiogenesis and tumor growth in vivo [57] . Goserelin is a synthetic analogue of luteinizing hormone-releasing hormone, used in the treatment of prostate cancer. Its half-life is rather short, so continuous application is needed to reach therapeutic relevant plasma concentrations in patients. Encapsulation into PEG-b-PCL micelles resulted in a depot effect with constant goserelin plasma levels and long-term suppression of serum testosterone over 28 days when administered s.c [110] . The use of combination therapies is a major strategy in the treatment of resistant cancers. The combination of potent inhibitors of efflux transporters and chemotherapeutics, for example, can increase the exposure of cancer cells to the cytotoxic drug and by this restore therapeutic effects [184] . At certain drug-todrug ratios, synergistic effects (in contrast to simple additive effects) can occur [185] . Whereas these combinations of drugs are often tested on in vitro cell culture models, the translation of results into the patient situation is difficult due to inter-and intra-individual differences in drug metabolism and pharmacokinetics (DMPK). The encapsulation of a specific combinations of drugs into a NP formulation and the subsequent synchronized delivery of this drug payload to the cancer cell can overcome this hurdle [184, [186] [187] [188] . Paclitaxel, cyclopamine, and gossypol were loaded in PEG-b-PCL micelles and used for the treatment of ovarian cancer xenografts. All tumor-bearing animals treated with the triple therapy NP survived (58 days), whereas 75% of all animals in the control group died during this period [189] . Local delivery of PEG-PCL NPs on e.g. the skin [60, 190, 191] or the eye [192] was used to increase the therapeutic effect at the site of action.
Targeted drug delivery
In contrast to non-targeted delivery systems, active targeting is directed towards specific, accessible receptors or epitopes preferentially (over)-expressed on target cells. The NP is designed to specifically interact with the cellular surface, increasing the NP binding to its target cell, retention at the site of action, and cellular uptake [174] . Various types of ligands such as antibodies or antibody fragments, aptamers, proteins, peptides, carbohydrates, and small molecules such as vitamins can be used for targeted drug delivery [193] . An overview of ligands used in combination with PEG-PCL NPs is shown in Table 2 and Fig. 4 . Different strategies were applied to conjugate targeting ligands to PEG- PCL NPs. Gou and coworkers produced mannan-functionalized PCEC NPs by passively adsorbing this linear polysaccharide to the NP surface [194] . Such non-covalent conjugation techniques were largely replaced by covalent conjugation [195] . A widely used strategy is the conjugation of ligands to amino-terminated PEG-PCL (e.g. NH 2 -PEG-b-PCL), carboxyl-terminated PEG-PCL, or maleimide-terminated PEG-PCL [49, 54, 56, 60, 64, 196, 197] . Pourcelle and coworkers developed a photoimobilization-based conjugation strategy using aryl azide "molecular clip". NHS-activated PEG-b-PCL was generated by light-induced conjugation of a bi-functional "molecular clip" (O-Succinimidyl-4-(p-azidophenyl)-N-butanoate) to PEG-b-PCL [198, 199] . Azide-modified PEGb-PCL was synthesized for the conjugation of alkyne-modified aptamers using "click" chemistry [145] . Typical conjugation strategies for PEG-PCL NPs are summarized in Fig. 5 . Doxorubicin was encapsulated into PEG-b-PCL micelles functionalized with hyaluronic acid (HA), a linear polysaccharide that can be used to target a variety of tumor. Ehrlich ascites tumor (EAT)-bearing mice were treated via tail vein injection over 7 days at a dose of 0.24 mg/kg/day. Tumor size was measured over 20 days. A 2.6-fold reduction in tumor volume after 20 days as compared to free doxorubicin was observed [164] . Paclitaxel-loaded PEG-b-PCL micelles decorated with aniopep-2, a specific ligand to low density lipoprotein receptor related protein 1 (LRP1) expressed on endothelial cells of the blood-brain barrier (BBB), were tested in an intracranial glioma mouse model [142, 200, 201] . PEG-b-PCL micelles were injected daily at dose of 10 mg/kg three times within 9 days and compared to Taxol™, the approved formulation of paclitaxel. Tumor volume in animals treated with targeted PEG-b-PCL micelles was reduced > 2-fold as compared to Taxol™. In addition, mean survival time (MST) was prolonged to 37 days, whereas mean survival time in animals treated with Taxol™ was 25 days only [118] . Dual targeted docetaxel loaded PEG-b-PCL micelles were modified with TGN, a peptide obtained by phage display to enhance BBB permeability, and with the aptamer AS1411, targeted against nucleolin, a protein highly expressed in glioma cells [91, 172] . Targeted PEG-b-PCL micelles showed an increased therapeutic efficiency in vivo as compared to free drug and non-targeted NPs. The MST of orthotropic glioma bearing mice was prolonged to 32 days, whereas animals treated with free drug had a MST of 18 days [172] . The density of the ligand on the NP surface is a critical characteristic for successful targeting. Quantification of the ligand/NP ratio was performed using radio-, fluorescent-, and immunogold-labeling of the targeting moiety [49, 160, 198, [202] [203] [204] . Scanning transmission electron microscopy can additionally give insight into the spatial organization of immunogoldlabeled ligands on the NP surface [205] . Multivalent binding enabled by high ligand densities on the NP surface can enhance binding affinity to the target receptor [206] . For example, PEG-b-PCL micelles were prepared with different ratios of PEG-b-PCL and folate-modified PEG-b-PCL. Cellular uptake was enhanced with increasing amounts of folate per micelle [207] . Similarly, PEG-b-PCL micelles decorated with a peptide ligand of the endothelial growth factor receptor (EGFR) showed maximal cellular uptake in EGFR overexpressing cells in vitro for micelles with the highest peptide surface density [208, 209] . However, loss of stealth properties by high ligand surface densities can reduce the NP targeting efficiency in vivo [202] . NC-1900, a vasopressin fragment analog with a great potential in the treatment of neurological disorders (i.e. spatial memory impairments) but with a poor permeation across the BBB, was encapsulated within PEG-b-PCL NPs [20, 210] . OX26, an antibody against the transferrin receptor that was used in braintargeting in various studies, was conjugated to these PEG-b-PCL NPs [20, 203, [211] [212] [213] . NPs with a high surface density of OX26 (i.e. 92 per NP) showed a significantly reduced AUC and no increase in brain delivery capacity. In contrast, the optimized formulation with 34 molecules of OX26 per NP was able to deliver its payload 2.6-fold more efficient to the brain as compared with non-modified NPs and improved scopolamine-induced learning and memory deficits when injected i.v. in Sprague-Dawley rats [20] . In another study, the neuroprotective peptide NAP was encapsulated in lactoferrin-modified PEG-b-PCL micelles. After intranasal administration in an in vivo Alzheimer model of mice, a neuroprotective effect was reached as shown by behavioral improvements and histological analysis [214] . PEG-b-PCL micelles were conjugated to a cell penetrating peptide (Tat). Modified micelles were able to deliver siRNA and fluorescently labeled dextran more efficient to the brain than non-modified PEG-b-PCL micelles or free dextran after intranasal administration [215, 216] . Table 2 ).
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PEG-b-PCL poly(lactic acid)-hydrid micelles were designed for oral vaccination. Modification of the NP surface with different peptidic and small molecular peptides resulted in enhanced cellular uptake and transport in vitro and increased immune response when administered orally in experimental animals [199] . The ease of chemical modification of PEG-PCL copolymers can thus be exploited to conjugate various ligands to the surface of PEG-PCL NPs and to implement drug targeting strategies. Detailed understanding of the NP-cell interaction as well as optimization of the ligand density is furthermore needed to improve the performance of these systems.
Stimuli-responsive nanoparticles and triggered drug release
Stimuli-responsive "smart" NPs, e.g. controlled drug release formulations, can improve therapeutic efficiency by increasing the drug release at the site of action. In such systems, drug release can be triggered by either externally applied or internal stimuli. Systems responsive to changes in e.g. pH, temperature, irradiation, magnetism, concentration gradients, or enzymatic activity were designed [217] . A schematic overview about PEG-PCL-based stimuli-responsive NPs is given in Fig. 6 and Table 3 .
Overexpression of matrix metalloproteases (MMP), especially MMP-2 and MMP-9, are linked with progression of cancer [218] . Thus, prodrug strategies depending on MMP activity are promising candidates to increase therapeutic selectivity to tumors [219] . A PEG-PCL copolymer with a MMP-cleavable peptide linker (PEG-b-Pep-b-PCL) was synthesized and used to produce campothecin-loaded micelles. After passive accumulation in the tumor, loss of stealth properties as a consequence of MMP-mediated detachment of PEG should lead to increased cellular uptake by tumor cells. Indeed, this formulation showed superior effects as compared to PEG-b-PCL micelles or free drug as shown by a high tumor accumulation of the drug and a reduced tumor volume in treated xenograft-bearing mice [220] . In another study, a cell-penetrating peptide with a MMP-cleavable protection Fig. 6 . Triggered drug release. Schematic representation of strategies for triggered drug release using PEG-PCL-based nanoparticles. Strategies are reviewed in Section 8.3 and Table 3 . Table 3 Design of stimuli-sensitive nanoparticles using PEG-PCL polymers. Strategies for triggered drug release and stimuli-responsive targeting are highlighted. group was conjugated to PEG-b-PCL micelles loaded with paclitaxel. Again, enzyme-triggered activation resulted in higher anti-tumor activity in vitro as well as in vivo [64] . PEG-b-PCL NPs with carboxylic functionalized PCL were synthesized for pH-responsive drug release, e.g. after oral administration. Vesicles were produced and loaded with various drugs. Whereas a slow and incomplete drug release was observed in acidic conditions, a burst release was obtained at pH > 7 [221] . Such systems could be used to implement targeting strategies for specific sections of the gastrointestinal tract (GIT) after oral application although a proof-of-concept in vivo is still missing.
Zhong and coworkers synthesized PEG-PCL copolymers containing a disulfide linkage (PEG-SS-PCL). Reductive sensitive micelles were produced and loaded with doxorubicin. At redox potentials similar to the physiological intracellular level, a complete release of doxorubicin was observed within 10 h, whereas only 20% of the drug was released in PBS [222] . Furthermore, PEG-SS-PCL micelles showed increased anti-tumor activity in experimental animals as compared to PEG-b-PCL micelles [223] .
PEG-b-PCL-gold nanorods loaded with doxorubicin were prepared for NIR triggered thermochemotherapy. When hybrid nanorods were irradiated with a NIR laser source, an increase in temperature and a triggered release of doxorubicin was observed [171, 224, 225] . The core of PEG-b-PCL micelles is crystalline at temperatures below the melting point of PCL. As soon as the temperature is elevated above the melting point of the micelle core (e.g. by NIR irradiation), increased drug release can be observed [226, 227] .
Huang and colleagues produced mixed micelles consisting of PEG-b-PCL and poly(N-isopropylacrylamide)-b-PCL (PNIPAM-PCL). Due to its spontaneous hydrophilic to hydrophobic transformation at physiological temperatures, PNIPAM builds hydrophobic domains on the micelle surface that have high affinity for toxic Aβ oligomers. These micelles were capable to inhibit the Aβ fibrillation process and to enhance proteolytic degradation of Aβ in vitro. They could thus be used as artificial scavengers in the therapy of Alzheimer's disease [228] . Another group synthesized star-shaped PEG-PCL-poly(acrylic acid) (PEG-PCL-PAA) and PEG-PCL-PNIPAM copolymers. These particles were sensitive to temperature, pH, and chemical reduction. Release of doxorubicin was enhanced upon exposure to those stimuli [229] .
Covalent chemical modification of PEG-PCL copolymers, synthesis of PEG-PCL tri-block copolymers, and production of PEG-PCL mixedmicelles was used to develop stimuli-responsive PEG-PCL NPs. Upon exposure to disease-related or externally applied triggers, these NPs showed increased drug release or cellular uptake in vitro and superior therapeutic effects induced in animal models.
Theranostics
Theranostics combine diagnosis, treatment, and monitoring of the therapeutic effect using a single nanocarrier system [230] [231] [232] [233] [234] . A variety of non-invasive diagnostic imaging tools such as NIR fluorescence imaging, magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) is in use [235] . These methods require contrast agents or probes, e.g. quantum dots (QDs), inorganic dyes, supramagnetic iron oxide NPs (SPIONs), gold NPs (GNPs), or radioisotopes [230, 235] . Some of these probes can be activated by external stimuli to exert an inherent therapeutic effect, e.g. in photodynamic or photothermal therapy [230] . Vesicles of PEG-b-PCL-tethered GNPs were used for photoacoustic imaging and enhanced photothermal therapy [236] . Dense packaging and specific orientation of GNPs in PEG-b-PCL nanohybrid vesicles induced strong NIR absorption by plasmon coupling and enabled tumor ablation and prolongation of the mean survival time in MDA-MB-435 tumor-bearing mice [236] . BBTe2FT, a small molecule with strong absorbance in the NIR window, was encapsulated in PEG-b-PCL micelles. A strong photoacoustic signal and a high photothermal conversion efficiency upon NIR laser irradiation resulted in a high anti-tumor efficiency in vitro and a high penetration depth of 4 cm in ex vivo tissue [237] . Alternatively, drugs (e.g. cytostatic compounds) can be administered simultaneously. SPIONs and doxorubicin were encapsulated in folate-targeted PEG-b-PCL micelles. These micelles showed efficient uptake in hepatoma cells and enhanced MRI T 2 -weighed signal in vitro and in vivo [238, 239] . In highly heterogeneous diseases such as cancer, patients could benefit from such personalized therapies. Inter-and intra-individual variability of tumors require adequate diagnosis and an adapted treatment, as for example the selection of patient populations that benefit from passive tumor accumulation (i.e. EPR effect) upon NP treatment. PEG-PCLbased theranostics were successfully used for the simultaneous detection and treatment of cancer diseases in vivo. Future challenges include the adaptation of this promising strategy to various diseases in combination with established biomarkers.
Delivery of nucleic acids
Nucleic acids are promising therapeutics for many diseases. Their metabolic instability requires drug delivery systems that protect them from rapid degradation in the circulation to enable efficient delivery to the target cells. Several strategies were used to implement gene delivery platforms using PEG-PCL NPs. Synthesis of tri-block copolymers by chemical modification of PEG-PCL or the preparation of mixed micelles using various copolymers showed promising results. Conjugation of positively charged cationic segments such as linear or branched poly (ethylene imine) (PEI) and poly(aminoethyl methacrylate) (PAMA) to PEG-b-PCL di-block copolymers results in PEG-b-PCL-b-PEI or PEG-b-PCL-b-PAMA tri-block copolymers. Alternatively, esterification of the mPEG-b-PCL hydroxyl group by acryloyl chloride and subsequent Michael-type addition of PEI was used [240, 241] . Optimizations in the self-assembly process and the molecular composition of the triblock copolymer resulted in efficient encapsulation of small interfering RNA (siRNA) and high gene delivery capacity [68, 241, 242] . PEG-b-PCL-b-PEI micelles loaded with siRNA, targeted against GAPDH, showed high transfection efficiency and were able to knock down target gene expression in vitro and in vivo when administered intratracheally [240] . Another PEG-PCL-PEI tri-block copolymer targeted to the folate receptor was used to simultaneously deliver doxorubicin and to knock down P-glycoprotein (P-gp) expression using siRNA. Micelles were able to restore sensitivity of MCF-7/ADR cells to doxorubicin in an attempt to treat multi-drug resistant (MDR) cancer [243] . Mixed micelles composed of PEG-b-PCL, poly(2-(dimethylamino)ethyl methacrylate)-b-PCL (PDMA-b-PCL), and pegylated anti-VEGF siRNA were produced. In addition, micelles were loaded with SN-38, a cytotoxic drug, and iron oxide nanoparticles for MRI contrast enhancement. This multi-component formulation was able to knock down VEGF expression, served as MRI contrast agent, and showed promising antitumor efficiency in vivo [244] . The high chemical stability of PEG-PCL copolymers can efficiently prevent the extracellular degradation of nucleic acid-based therapeutics: The future challenges lay in the extrapolation from test systems and animal models to possible clinical applications in human.
Conclusion
PEG-PCL NPs are promising candidates as drug delivery tools characterized by a high biocompatibility, biodegradability, and longcirculating properties. Chemical versatility and ease of modification led to the development of drug carriers for targeted and non-targeted delivery of various drugs ranging from small molecules to macromolecules such as proteins or nucleic acids. Although no candidate reached market approval from regulatory authorities so far, further improvement and research on PEG-PCL-based nanomedicines will increase the chance for a clinical application in humans. As lesson from history, the development of liposomal drug delivery systems have shown that transferring novel technologies from bench to bedside needs to overcome several hurdles and can take decades [245] . The implication of scalable and reproducible production processes using e.g. microfluidics and extensive physico-chemical characterization should therefore be addressed. With this knowledge, disease-driven design and development of PEG-PCL nanoDDS can enhance the therapeutic efficacy and potential patient benefit. Long-term safety and efficacy studies in vivo need to be performed. Suitable preclinical models should be selected carefully and used for the development of patient pre-selection tools [246, 247] . This will open up paths for first in human trials and clinical implication of promising PEG-PCL-based nanoDDS candidates. At present, a vast number of synthetic polymers are developed in preclinical research. PEG-b-PCL-based micelles are among the most advanced and best-characterized systems and therefore have a great potential to successfully enter translational research in the near future.
